Enhancement of Anti-tumor Cytotoxicity of Expanded gamma delta T Cells by Stimulation with Monocyte-derived Dendritic Cells

被引:13
|
作者
Saito, Anri [1 ,2 ]
Narita, Miwako [1 ]
Yokoyama, Ayumi [1 ]
Watanabe, Norihiro [1 ,2 ]
Tochiki, Nozomi [1 ]
Satoh, Noriyuki [1 ]
Takizawa, Jun [2 ]
Furukawa, Tatsuo [3 ]
Toba, Ken [2 ]
Fuse, Ichiro [4 ]
Aizawa, Yoshifusa [2 ]
Shinada, Shohji [5 ]
Takahashi, Masuhiro [1 ]
机构
[1] Niigata Univ, Grad Sch Hlth Sci, Lab Hematol & Oncol, Niigata, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Hematol, Niigata, Japan
[3] Niigata Univ, Med & Dent Gen Hosp, Div Stem Cell Transplantat, Niigata, Japan
[4] Niigata Univ, Med & Dent Gen Hosp, Biosci Med Res Ctr, Niigata, Japan
[5] Niigata Prefecture Red Cross Blood Ctr, Niigata, Japan
关键词
gamma delta T cells; monocyte-derived dendritic cells; CD69; anti-tumor cytotoxicity; cellular immunotherapy;
D O I
10.3960/jslrt.47.61
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to establish the method of generating powerful gd T cells for anti-tumor immunotherapy, we investigated the effects of monocyte-derived dendritic cells (mo-DCs) on anti-tumor cytotoxicity of expanded gamma delta T cells. Activation of gamma delta T cells co-cultured for 2-3da ys with immature or mature mo-DCs was evaluated by CD69 expression and anti-tumor cytotoxicity using two assays : the 5-(and 6-) carboxyfluorescein diacetate, succinimidyl ester-based cytotoxicity assay and the calcein-AM-based Terascan assay. gamma delta T cells were used as effector cells and myeloma cell line (RPMI8226) or chronic myelogenous leukemia blastic crisis cell line (C2F8) were used as target cells. CD69 expression on gamma delta T cells was enhanced by co-culture with both immature and mature mo-DCs in a cell-number-dependent fashion. CD69 expression was enhanced after addition of mo-DCs of either autologous or allogeneic origin. Activation of gamma delta T cells with mo-DCs enhanced anti-tumor cytotoxicity of gamma delta T cells against RPMI8226 and C2F8 in an effector-to-target ratio-dependent manner. Activation of gamma delta T cells by mo-DCs was associated with the enhancement of anti-tumor cytotoxicity of gamma delta T cells. Potent gamma delta T cells activated by mo-DCs were considered to be applicable to an efficient gamma delta T cell-mediated immunotherapy for tumors.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 50 条
  • [21] Gene expression analysis in human monocytes, monocyte-derived dendritic cells, and α-galactosylceramide-pulsed monocyte-derived dendritic cells
    Lapteva, N
    Nieda, M
    Ando, Y
    Nicol, A
    Ide, K
    Yamaura, A
    Hatta-Ohashi, Y
    Egawa, K
    Juji, T
    Tokunaga, K
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 289 (02) : 531 - 538
  • [22] Differences in T-helper polarizing capability between human monocyte-derived dendritic cells and monocyte-derived Langerhans'-like cells
    Rajkovic, Ivan
    Dragicevic, Ana
    Vasilijic, Sasa
    Bozic, Biljana
    Dzopalic, Tanja
    Tomic, Sergej
    Majstorovic, Ivana
    Vucevic, Dragana
    Djokic, Jelena
    Balint, Bela
    Colic, Miodrag
    IMMUNOLOGY, 2011, 132 (02) : 217 - 225
  • [23] Modulation of anti-tumor responses of gamma delta T cells by TLR agonists
    Shojaei, H.
    Oberg, H.
    Kunz, M.
    Kabelitz, D.
    Wesch, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 74 - 74
  • [24] In vitro expansion of blood γδ T cells in patients with myeloma/lymphoma and anti-tumor cytotoxicity of the expanded γδ T cells.
    Saito, Anri
    Narita, Miwako
    Watanabe, Norihiro
    Tochiki, Nozorni
    Hiroi, Yumi
    Shirasaki, Takayoshi
    Takizawa, Jun
    Furukawa, Tatsuo
    Toba, Ken
    Aoki, Sadao
    Aizawa, Yoshifusa
    Takahashi, Masuhiro
    BLOOD, 2006, 108 (11) : 51B - 51B
  • [25] Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells
    Ammon, C
    Meyer, SP
    Schwarzfischer, L
    Krause, SW
    Andreesen, R
    Kreutz, M
    IMMUNOLOGY, 2000, 100 (03) : 364 - 369
  • [26] Fucoidan stimulation induces a functional maturation of human monocyte-derived dendritic cells
    Yang, Meixiang
    Ma, Chunhong
    Sun, Jintang
    Shao, Qianqian
    Gao, Wenjuan
    Zhang, Yan
    Li, Zewu
    Xie, Qi
    Dong, Zhaogang
    Qu, Xun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (13-14) : 1754 - 1760
  • [27] The anti-tumor agent topotecan has an impact on the activation of human monocyte derived dendritic cells
    Trojandt, S.
    Grabbe, S.
    Reske-Kunz, A. B.
    Bros, M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 78 - 78
  • [28] Antigen presentation by mouse monocyte-derived cells: Re-evaluating the concept of monocyte-derived dendritic cells
    Coillard, Alice
    Segura, Elodie
    MOLECULAR IMMUNOLOGY, 2021, 135 : 165 - 169
  • [29] Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
    Kalijn F. Bol
    Erik H. J. G. Aarntzen
    Jeanette M. Pots
    Michel A. M. Olde Nordkamp
    Mandy W. M. M. van de Rakt
    Nicole M. Scharenborg
    Annemiek J. de Boer
    Tom G. M. van Oorschot
    Sandra A. J. Croockewit
    Willeke A. M. Blokx
    Wim J. G. Oyen
    Otto C. Boerman
    Roel D. M. Mus
    Michelle M. van Rossum
    Chantal A. A. van der Graaf
    Cornelis J. A. Punt
    Gosse J. Adema
    Carl G. Figdor
    I. Jolanda M. de Vries
    Gerty Schreibelt
    Cancer Immunology, Immunotherapy, 2016, 65 : 327 - 339
  • [30] Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
    Bol, Kalijn F.
    Aarntzen, Erik H. J. G.
    Pots, Jeanette M.
    Nordkamp, Michel A. M. Olde
    van de Rakt, Mandy W. M. M.
    Scharenborg, Nicole M.
    de Boer, Annemiek J.
    van Oorschot, Tom G. M.
    Croockewit, Sandra A. J.
    Blokx, Willeke A. M.
    Oyen, Wim J. G.
    Boerman, Otto C.
    Mus, Roel D. M.
    van Rossum, Michelle M.
    van der Graaf, Chantal A. A.
    Punt, Cornelis J. A.
    Adema, Gosse J.
    Figdor, Carl G.
    de Vries, I. Jolanda M.
    Schreibelt, Gerty
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (03) : 327 - 339